Current Pharmaceutical Analysis 

About: Current Pharmaceutical Analysis is an academic journal published by Bentham Science Publishers. The journal publishes majorly in the area(s): Chemistry & High-performance liquid chromatography. It has an ISSN identifier of 1573-4129. Over the lifetime, 822 publications have been published receiving 5488 citations.

Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis

Abstract: Chemical investigation of many bacterial and fungal, as well as plant species has revealed the presence of in- teresting compounds derived from naphthalene - 1,4-naphthoquinones and rarely also 1,2-naphthoquinones. They were detected in many species of families Bignoniaceae, Droseraceae, Plumbaginace, Boraginaceae, Juglandaceae as well as in species of small families, such as Dioncophyllaceae or Acanthaceae. Naphthoquinones have very interesting spectrum of biological actions, including antibiotic, antiviral, anti-inflammatory, antipyretic, antiproliferative and cytotoxic effects. Because of these properties the plants containing them are used in folk medicines, mainly by natives in Asia, where espe- cially Chinese medicine uses aerial as well as subterranean parts of these plants for hundreds years, and South America. The utilizing of naphthoquinones for medicinal purposes and their occurrence in nature is reviewed and discussed. Moreover, we review analytical techniques using for their analysis.

Lipid Disorders in Diabetes Mellitus and Current Management

Abstract: Lipid disorders are common in diabetes mellitus (DM), and play crucial roles in the development of diabetic cardiovascular complications. Diabetic dyslipidemia is characterized by hypertriglyceridemia, increased levels of very low density lipoproteins (VLDL), small dense low density lipoprotein (LDL), and decreased levels of high density lipoprotein (HDL)-cholesterol. The activity of lipoprotein lipase is reduced in diabetic patients, which attenuates the lipolysis of triglyceride-rich lipoproteins and the uptake of free fatty acids. The increased uptake of triglycerides in liver promotes the production of VLDL. Hypertriglyceridemia promotes the exchange of cholesteryl ester from HDL to VLDL or LDL for triglycerides. Obesity or nephropathy deteriorates the dyslipidemia in DM patients. The initial management of lipid disorders in diabetic patients without cardiovascular disease is lifestyle intervention and glucose control. The abnormalities in the metabolism of LDL or HDL in diabetic patients often require pharmacological intervention. Target of LDL-cholesterol (LDL-c) is more restrict in diabetic patients than in non-diabetic subjects. Treatment with HMG-CoA reductase inhibitors (statins) effectively reduces LDL-c and cardiac events, and that was associated with moderately increases in HDL-c. The combination of ezetimibe with a statin helps to achieve LDL-c target in patients with unsatisfactory cholesterol lowering by statin alone. Fibrates (PPAR-α agonists) or PPAR-γ agonists reduce the levels of triglycerides and moderately elevate HDL-c. PPAR-γ agonists also improve insulin sensitivity. Cholesteryl ester transfer protein inhibitors may dramatically increase HDL-c. Lipid management has been considered as an effective approach to reduce cardiovascular risk in diabetes.

Enantioselective Toxicity and Carcinogenesis

Abstract: In a non-chiral environment, the enantiomers of a racemate possess the same physico-chemical properties but in the biological systems they possess different activities. One of the enantiomers may be more toxic or carcinogenic, and, therefore, the present data available on the toxicity and carcinogenesis of the racemic mixtures of these chiral pollutants are not reliable and need modification in terms of the enantioselective toxicity and carcinogenesis. It is essential to explore the enantioselective toxicity and carcinogenesis due to the different enantiomers of the chiral pollutants. The knowledge of the stereoselective metabolisms of the chiral pollutants may be useful for the treatment of cancer and other diseases. The enantioselective toxicity and carcinogenesis due to the chiral pesticides, pollutants and some drugs have been discussed in this review article.

Critical Review of Development, Validation, and Transfer for High Throughput Bioanalytical LC-MS/MS Methods

Abstract: Swift growth in the use of LC-MS/MS for the analysis of drugs in biological matrices has been compelled by the need for timely and high-quality data at many stages in drug discovery and development process: from high throughput screening of drug candidates and rapid data generation for pre-clinical studies to almost 'real-time' analysis of clinical samples. Prompt and rational method development, validation, and transfer play a pivotal role in achieving the goals of "faster, better, and cheaper" for pharmacokinetic studies since this could easily account for more than 50% of the time and labor resources for a moderate-sized project. Strategy for rational method development, validation and transfer has been largely kept as institutional knowledge but rarely appeared in literature. In this review article, strategies for developing and validating robust high throughput LC-MS/MS methods will be critically reviewed and discussed. Automated sample preparation, fast chromatography, minimization of matrix effects, and strategy of narrowing the gap between validation and incurred sample analysis are just a few topics covered in this review. Other interesting approaches for improving method efficiency and ruggedness such as direct injection SPE and liquid/liquid extracts as well as multiplexing of LC columns will also be discussed. Potential pitfalls during method development and validation are pointed out. At the end, the question "how fast is fast enough and how fast is too fast?" will be answered after considering all aspects of the method development and validation.